CareDx, Inc. (CDNA)

Market Cap	3.58B +342.9%
Revenue (ttm)	458.09M +34.4%
Net Income	111.01M +90.9%
EPS	2.12 +112.5%
Shares Out	51.73M
PE Ratio	32.64
Forward PE	64.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	732,079
Open	68.54
Previous Close	69.16
Day's Range	67.43 - 70.48
52-Week Range	14.03 - 72.71
Beta	2.38
Analysts	Buy
Price Target	61.67 (-10.89%)
Earnings Date	Oct 29, 2026

About CDNA

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about dist...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 17, 2014
• Employees: 765
• Stock Exchange: Nasdaq
• Ticker Symbol: CDNA
• Website: https://caredx.com

Analyst Summary

According to 7 analysts, the average rating for CDNA stock is "Buy." The 12-month stock price target is $61.67, which is a decrease of -10.89% from the latest price.

Price Target

$61.67

(-10.89% downside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 24, 2026

Data Sources Report a data error